Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder

被引:16
作者
Johansson, J-E [1 ]
Remberger, M. [2 ]
Lazarevic, V. Lj [3 ]
Hallbook, H. [4 ]
Wahlin, A. [5 ]
Kimby, E. [6 ]
Juliusson, G. [3 ]
Omar, H. [6 ]
Hagglund, H. [6 ]
机构
[1] Sahlgrens Univ Hosp, Dept Hematol & Coagulat, S-41345 Gothenburg, Sweden
[2] Karolinska Inst, Div Clin Immunol & Transfus Med, Stockholm, Sweden
[3] Lund Univ, Dept Hematol, Skane Univ Hosp, Lund, Sweden
[4] Univ Uppsala Hosp, Dept Hematol, Uppsala, Sweden
[5] Univ Hosp, Ctr Canc, Dept Hematol, Umea, Sweden
[6] Karolinska Univ Hosp Huddinge, Hematol Ctr, Stockholm, Sweden
关键词
allogeneic; transplantation; Hodgkin's lymphoma; post transplant lymphoproliferative disorder; reduced intensity conditioning; BONE-MARROW-TRANSPLANTATION; RANDOMIZED-TRIAL; DISEASE; RISK; EXPERIENCE; REGIMEN; BLOOD;
D O I
10.1038/bmt.2010.238
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL. Bone Marrow Transplantation (2011) 46, 870-875; doi: 10.1038/bmt.2010.238; published online 18 October 2010
引用
收藏
页码:870 / 875
页数:6
相关论文
共 24 条
[1]   Long-term results of blood and marrow transplantation for Hodgkin's lymphoma [J].
Akpek, G ;
Ambinder, RF ;
Piantadosi, S ;
Abrams, RA ;
Brodsky, RA ;
Vogelsang, GB ;
Zahurak, ML ;
Fuller, D ;
Miller, CB ;
Noga, SJ ;
Fuchs, E ;
Flinn, IW ;
O'Donnell, P ;
Seifter, EJ ;
Mann, RB ;
Jones, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) :4314-4321
[2]   Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].
Alvarez, I ;
Sureda, A ;
Caballero, MD ;
Urbano-Ispizzua, A ;
Ribera, JM ;
Canales, M ;
García-Conde, J ;
Sanz, G ;
Arranz, R ;
Bernal, MT ;
de la Serna, J ;
Díez, JL ;
Moraleda, JM ;
Rubió-Félix, D ;
Xicoy, B ;
Martínez, C ;
Mateos, MV ;
Sierra, J .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183
[3]   Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen [J].
Anderlini, P ;
Saliba, R ;
Acholonu, S ;
Okoroji, GJ ;
Donato, M ;
Giralt, S ;
Andersson, B ;
Ueno, NT ;
Khouri, I ;
De Lima, M ;
Hosing, C ;
Cohen, A ;
Ippoliti, C ;
Romaguera, J ;
Rodriguez, MA ;
Pro, B ;
Fayad, L ;
Goy, A ;
Younes, A ;
Champlin, RE .
BONE MARROW TRANSPLANTATION, 2005, 35 (10) :943-951
[4]   Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].
Anderlini, Paolo ;
Saliba, Rima ;
Acholonu, Sandra ;
Giralt, Sergio A. ;
Andersson, Borje ;
Ueno, Naoto T. ;
Hosing, Chitra ;
Khouri, Issa F. ;
Couriel, Daniel ;
de Lima, Marcos ;
Qazilbash, Muzaffar H. ;
Pro, Barbara ;
Romaguera, Jorge ;
Fayad, Luis ;
Hagemeister, Frederick ;
Younes, Anas ;
Munsell, Mark F. ;
Champlin, Richard E. .
HAEMATOLOGICA, 2008, 93 (02) :257-264
[5]   ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].
ANDERSON, JE ;
LITZOW, MR ;
APPELBAUM, FR ;
SCHOCH, G ;
FISHER, LD ;
BUCKNER, CD ;
PETERSEN, FB ;
CRAWFORD, SW ;
PRESS, OW ;
SANDERS, JE ;
BENSINGER, WI ;
MARTIN, PJ ;
STORB, R ;
SULLIVAN, KM ;
HANSEN, JA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350
[6]   Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma [J].
Burroughs, Lauri M. ;
O'Donnell, Paul V. ;
Sandmaier, Brenda M. ;
Storer, Barry E. ;
Luznik, Leo ;
Symons, Heather J. ;
Jones, Richard J. ;
Ambinder, Richard F. ;
Maris, Michael B. ;
Blume, Karl G. ;
Niederwieser, Dietger W. ;
Bruno, Benedetto ;
Maziarz, Richard T. ;
Pulsipher, MichaelA. ;
Petersen, Finn B. ;
Storb, Rainer ;
Fuchs, Ephraim J. ;
Maloney, David G. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) :1279-1287
[7]   Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma [J].
Castagna, Luca ;
Sarina, Barbara ;
Todisco, Elisabetta ;
Magagnoli, Massimo ;
Balzarotti, Monica ;
Bramanti, Stefania ;
Mazza, Rita ;
Anastasia, Antonella ;
Bacigalupo, Andrea ;
Aversa, Franco ;
Soligo, Davide ;
Giordano, Laura ;
Santoro, Armando .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (04) :432-438
[8]  
Curtis RE, 1999, BLOOD, V94, P2208
[9]   Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma [J].
Devetten, Marcel P. ;
Hari, Parameswaran N. ;
Carreras, Jeanette ;
Logan, Brent R. ;
van Besien, Koen ;
Bredeson, Christopher N. ;
Freytes, Cesar O. ;
Gale, Robert Peter ;
Gibson, John ;
Giralt, Sergio A. ;
Goldstein, Steven C. ;
Gupta, Vikas ;
Marks, David I. ;
Maziorz, Richard T. ;
Vase, Julie M. ;
Lazarus, Hillard M. ;
Anderlini, Paolo .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (01) :109-117
[10]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509